All Products
Metabolic
About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed April 2018)
Empagliflozin (Jardiance®)
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of cardiovascular death in patients with established cardiovascular disease.
Empagliflozin Metformin HCl (Jardiance Duo®)
Empagliflozin + Metformin HCl (Jardiance Duo®) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate.
Linagliptin (Trajenta®)
Treatment of adults with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise, as monotherapy or as add on to metformin, sulphonylureas, thiazolidinediones, insulin (with or without metforminand/or pioglitazone and/or sulphonylureas or metformin plus SGLT2 inhibitors.
Linagliptin Metformin HCl (Trajenta Duo®)
Linagliptin + Metformin HCl (Trajenta Duo®) is indicated as adjunct to exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin HCl is appropriate.
Empagliflozin + Linagliptin (Glyxambi®)
Empagliflozin + Linagliptin (Glyxambi®) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
1 film-coated tablet contains 10 mg empagliflozin and 5 mg linagliptin or 25 mg empagliflozin and 5 mg linagliptin.
Cardiovascular
Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).
1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.
Dabigatran etexilate (Pradaxa®)
Prevention of strokes and blood clots in patients with abnormal heart rhythm (atrial fibrillation). Primary prevention of venous thrombo-embolic events (VTE) in adults after elective total hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and secondary prevention of recurrent DVT and PE in adults.
Oncology
Cancer takes. Takes away loved ones, time and untapped potential. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.
Afatinib (Giotrif®)
As monotherapy, it is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) Tyrosine kinase inhibitor (TKI) naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) and treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.1
1. Afatinib (Giotrif®) Prescribing Information, July 24, 2017